Valethamate Bromide

Valethamate Bromide (CAS No.: 90-22-2) is a synthetic small molecule anticholinergic and peripheral antispasmodic research reagent that is commonly classified within autonomic pharmacology and smooth muscle biology studies, with a functional profile characterized by antagonism of muscarinic acetylcholine receptors at cervical smooth muscle associated sites together with inhibition of nicotinic neuronal receptor signaling in autonomic ganglionic transmission, leading to reduced cholinergic excitatory tone, attenuation of spasm related contractile responses, suppression of glandular secretory drive, and facilitation of smooth muscle relaxation in experimental systems relevant to cervical tissue dynamics and labor associated biomechanical processes; in biomedical research and early drug discovery workflows, it is primarily used as a reference modulator for cholinergic pathway interrogation, receptor level mechanism mapping, and phenotypic screening of contractility endpoints, while published quantitative potency data are limited and context dependent, so activity is generally treated as occurring across broad pharmacological concentration windows from nanomolar to micromolar ranges depending on assay format, receptor subtype context, and tissue preparation, and its use in cell based assays, ex vivo smooth muscle preparations, and animal pharmacology models is typically designed to evaluate autonomic control of spasm and dilation related physiology, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives.